CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 82 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01700829
NCT01700829Phase 4Completed
CompareCT.gov

Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression

New York State Psychiatric Institute·interventional·Posted Oct 4, 2012·Updated Mar 11, 2020

In Brief

A Phase 4 clinical trial evaluating Ketamine and Midazolam for Major Depressive Disorder and Suicidal Ideation. Completed, enrolled 82 participants across 1 site.

Detailed Summary

This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression. The first drug, Ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Suicidal Ideation
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2012
Enrollment StartJun 1, 2012
Primary CompletionJan 12, 2017
Study CompletionJul 31, 2017
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 13.7 years ago

Interventions

Ketaminedrug

Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes

Midazolamdrug

Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes